[HTML][HTML] Immune checkpoint inhibitors: recent progress and potential biomarkers
Cancer growth and progression are associated with immune suppression. Cancer cells
have the ability to activate different immune checkpoint pathways that harbor …
have the ability to activate different immune checkpoint pathways that harbor …
[HTML][HTML] Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment
Y Song, Y Fu, Q Xie, B Zhu, J Wang… - Frontiers in …, 2020 - frontiersin.org
Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …
therapy. This is mainly associated with the successful development of immune checkpoint …
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Answer questions and earn CME/CNE To update the melanoma staging system of the
American Joint Committee on Cancer (AJCC) a large database was assembled comprising> …
American Joint Committee on Cancer (AJCC) a large database was assembled comprising> …
Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer
Importance Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate
dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) …
dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) …
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
M Nishino, NH Ramaiya, H Hatabu… - Nature reviews Clinical …, 2017 - nature.com
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm
shift in the treatment of advanced-stage cancers. The promising antitumour activity of …
shift in the treatment of advanced-stage cancers. The promising antitumour activity of …
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with …
S Diem, S Schmid, M Krapf, L Flatz, D Born, W Jochum… - Lung cancer, 2017 - Elsevier
Objectives Immunotherapy with the programmed death receptor-1 (PD-1) antibody
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) …
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) …
The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
EZ Keung, JE Gershenwald - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: The eighth edition of the American Joint Committee on Cancer (AJCC)
melanoma staging system was implemented in the United States on 1 January 2018. Areas …
melanoma staging system was implemented in the United States on 1 January 2018. Areas …
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Background The combination of cobimetinib with vemurafenib improves progression-free
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …
[HTML][HTML] Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
V Huber, C Camisaschi, A Berzi, S Ferro… - Seminars in cancer …, 2017 - Elsevier
The link between cancer metabolism and immunosuppression, inflammation and immune
escape has generated major interest in investigating the effects of low pH on tumor …
escape has generated major interest in investigating the effects of low pH on tumor …
The “cancer immunogram”
The impact of cancer immunotherapy on clinical cancer care is growing rapidly. However,
different immunotherapies remedy distinct problems in cancer–immune system interactions …
different immunotherapies remedy distinct problems in cancer–immune system interactions …